Assess whether RWE can replace or only supplement an RCT (fa6123)

Situation

Pharmacovigilance work in an RWE group proposing a post-marketing study instead of a new RCT now turns on RWE can replace or because a competitor label that just got a narrower indication put RWE protocol that may not meet regulator expectations in play. RWE evidence-strategy director should say what RWE protocol that may not meet regulator expectations proves.

Decision

RWE evidence-strategy director in an RWE group proposing a post-marketing study instead of a new RCT must choose RWE can replace / Only supplement an RCT using RWE protocol that may not meet regulator expectations after a competitor label that just got a narrower indication.

Hypotheses to test

• RWE evidence-strategy director can defend RWE can replace from RWE protocol that may not meet regulator expectations after a competitor label that just got a narrower indication in a Pharma & Life Sciences challenge.
• RWE evidence-strategy director cannot defend RWE can replace from RWE protocol that may not meet regulator expectations; Only supplement an RCT is what the extract actually supports after a competitor label that just got a narrower indication.
• A competitor label that just got a narrower indication never reached the population in RWE protocol that may not meet regulator expectations — reopen intake, do not close RWE can replace or.
• Two facts in RWE protocol that may not meet regulator expectations after a competitor label that just got a narrower indication conflict for RWE evidence-strategy director; hold this Pharmacovigilance file.

Analysis required

• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on RWE can replace or.
• Check whether RWE protocol that may not meet regulator expectations supports the labeled claim RWE evidence-strategy director would keep.
• For this Pharma & Life Sciences Pharmacovigilance file, read RWE protocol that may not meet regulator expectations against a competitor label that just got a narrower indication and write the one fact that would move RWE can replace or for RWE evidence-strategy director.

Recommendation

Choose RWE can replace / Only supplement an RCT on this Pharma & Life Sciences / Pharmacovigilance packet (RWE protocol that may not meet regulator expectations after a competitor label that just got a narrower indication). Lead with the Pharma & Life Sciences option RWE protocol that may not meet regulator expectations can support after a competitor label that just got a narrower indication, then the two facts that force it, then the Monday action for RWE evidence-strategy director in an RWE group proposing a post-marketing study instead of a new RCT.